Childhood Cancer Research

Share

Too many types of childhood cancer still have no known cure or treatment. In 2017, more than 15,000 children under age 19 will be diagnosed with cancer. 

We must ensure that researchers have the essential tools to fight childhood cancer and make sure children with cancer not only survive, but thrive. 

 

Over 15,000 U.S. children under age 19 will be diagnosed with cancer in 2017.

Take Action

Photo of children playing together

Tell Congress to Support Childhood Cancer and Pass the STAR Act

This lifesaving legislation will aid in the development of new treatments and improve the quality of life for kids not only while they receive cancer treatments, but throughout the rest of their lives.

Latest Updates

October 16, 2017
National

Melissa Horn first knew something was wrong when she lost her voice during her senior year in high school. A visit to the doctor confirmed a diagnosis of Hodgkin’s Lymphoma. Last month, fourteen years after her diagnosis, Melissa spoke at a briefing in the U.S. Capitol to share her story

Cancer Candor Blog
September 27, 2017

In honor of Childhood Cancer Awareness Month, Missouri Deputy ACT Lead Allison Johnson shares her experience as a childhood cancer survivor and advocate for the childhood cancer community in a guest blog.

September 6, 2017
National

Childhood cancer is the leading cause of disease-related death among children ages one to 19. Breakthroughs in childhood cancer research have led to more and more children surviving their cancer diagnosis, but progress in treating certain types of cancer remains limited. And, children who survive cancer, often must deal with

August 30, 2017

The Research to Accelerate Cures and Equity (RACE) for Children Act encourages new research for childhood cancers by changing the drug development process. There are many cancer drugs currently in development, but most are specifically focused on adult cancers. The RACE Act works to ensure that the innovation occurring for

Childhood Cancer Research Resources

ACS CAN’s official endorsement of the RACE for Children Act, a bill that will encourage new research and development in childhood cancer.

This report examines the drug development landscape for childhood cancer, identifying scientific, logistical, economic and ethical challenges that are unique to pediatric cancer drug development.